Adding Thymosin Alpha-1 to Interferon Therapy Improves Hepatitis C Treatment Response
Combining thymosin alpha-1 with interferon-alpha produced higher sustained response rates in hepatitis C patients compared to interferon alone.
Quick Facts
What This Study Found
Thymosin alpha-1 (1 mg twice weekly) combined with interferon-alpha-2b (3 MU three times weekly) produced superior biochemical and virological responses compared to interferon alone in treatment-naive chronic hepatitis C patients.
Key Numbers
How They Did This
Randomized controlled trial comparing IFN-alpha-2b + thymosin alpha-1 (n=17) versus IFN-alpha-2b alone (n=17) in treatment-naive chronic hepatitis C patients. Assessed biochemical (ALT normalization) and virological (HCV RNA) response.
Why This Research Matters
Hepatitis C was a major global health burden in 1998. Finding that thymosin alpha-1 could enhance interferon therapy offered a way to improve cure rates for a disease that was difficult to treat at the time.
The Bigger Picture
While direct-acting antivirals have since revolutionized hepatitis C treatment, this study demonstrated thymosin alpha-1's ability to boost antiviral immune responses — a principle that remains relevant for other viral infections where immune enhancement could improve treatment outcomes.
What This Study Doesn't Tell Us
Small sample size (17 per group). Preliminary results without long-term follow-up. The hepatitis C treatment landscape has changed dramatically since this study.
Questions This Raises
- ?Does thymosin alpha-1 enhance antiviral immunity through T-cell activation specifically?
- ?Could thymosin alpha-1 boost treatment response for other viral infections?
- ?What is the optimal dose of thymosin alpha-1 for immune enhancement?
Trust & Context
- Key Stat:
- 17 vs 17 patients Combination therapy with thymosin alpha-1 showed superior biochemical and virological response rates over interferon alone
- Evidence Grade:
- Moderate evidence from a small randomized trial. Clear methodology but limited by sample size and preliminary nature of results.
- Study Age:
- Published in 1998. Hepatitis C treatment has been revolutionized by direct-acting antivirals, making interferon-based regimens largely obsolete. However, thymosin alpha-1's immune-boosting principle remains relevant.
- Original Title:
- Interferon and thymosin combination therapy in naive patients with chronic hepatitis C: preliminary results.
- Published In:
- Liver, 18(5), 366-9 (1998)
- Authors:
- Moscarella, S, Buzzelli, G, Romanelli, R G, Monti, M, Giannini, C, Careccia, G, Marrocchi, E M, Zignego, A L
- Database ID:
- RPEP-00478
Evidence Hierarchy
Frequently Asked Questions
What is thymosin alpha-1?
Thymosin alpha-1 is a peptide naturally produced by the thymus gland that enhances immune system function, particularly T-cell activity. It has been studied as an adjunct therapy for viral infections and cancer.
Is this treatment still used for hepatitis C?
No. Hepatitis C is now treated with direct-acting antiviral drugs that cure over 95% of patients. However, thymosin alpha-1's ability to boost antiviral immunity remains of interest for other conditions.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-00478APA
Moscarella, S; Buzzelli, G; Romanelli, R G; Monti, M; Giannini, C; Careccia, G; Marrocchi, E M; Zignego, A L. (1998). Interferon and thymosin combination therapy in naive patients with chronic hepatitis C: preliminary results.. Liver, 18(5), 366-9.
MLA
Moscarella, S, et al. "Interferon and thymosin combination therapy in naive patients with chronic hepatitis C: preliminary results.." Liver, 1998.
RethinkPeptides
RethinkPeptides Research Database. "Interferon and thymosin combination therapy in naive patient..." RPEP-00478. Retrieved from https://rethinkpeptides.com/research/moscarella-1998-interferon-and-thymosin-combination
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.